1Slamon DJ, Clark GM, Wong SG, et ol. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987, 235 (4785): 177- 182.
2Smith I, Procter M, Gelber RD, et 01. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial [J]. Lancet, 2007, 369 (9555) : 29-36.
3Amodio R, Zarcone M, Cusimano R, et ol. Target therapy in HER2-overexpressing breast cancer patients [J]. OMICS, 2011, 15 (6): 363-367.
4Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer [J]. Science, 1989, 244 (4905): 707-712.
5Marin-Aguilera M, Mengual L, Ribal MJ, et ol. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer [J]. Cancer Genet Cytogenet, 2007, 173 (2): 131-135.
6Dewald G, Stallard R, A1 Saadi A, et d. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes [J]. Am J Med Genet, 1998, 76 (4): 318-326.
7Lan C, Liu JM, Liu TW, et ol. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis [J]. Am J Clin Pathol, 2005, 124 (1): 97-102.
8Dolan M, Shover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice [J]. Am J Clin Pathol, 2005, 123 (5): 766- 770.
